CBD Shows Promise But Lacks Broad Regulatory Approval: A Sobering Review of the Evidence

Only Epidiolex and Sativex have met gold-standard evidence requirements for regulatory approval; most marketed cannabis products fall far short of pharmaceutical quality standards, and a 2024 narrative review from the University of São Paulo argues the field is expanding well beyond what the science currently supports.

Why This Matters

CBD products have saturated consumer and clinical markets worldwide, generating enormous patient demand and a parallel stream of therapeutic claims that far outpace rigorous evidence. Clinicians face daily questions about CBD for conditions ranging from chronic pain to anxiety to neurodegeneration, often from patients already using products of unknown quality. The gap between market reality and regulatory science has become a patient safety issue, particularly for vulnerable populations including children, pregnant women, and individuals with psychiatric vulnerabilities. This review arrives at a moment when that gap demands clear-eyed clinical appraisal.

Clinical Summary

Cannabidiol (CBD) has attracted substantial attention as a therapeutic agent due to its lack of psychotomimetic effects, absence of abuse potential, and generally favorable tolerability profile across a wide dose range. A 2024 narrative review by researchers at the University of São Paulo’s Ribeirão Preto Medical School, published in Pharmaceuticals, synthesizes CBD’s pharmacology, the clinical evidence base for approved and unapproved indications, and the regulatory and quality-control landscape surrounding commercially available cannabis-derived products. CBD’s mechanisms of action are complex and multitarget, involving serotonin 5-HT1A receptors, TRPV1 channels, GPR55 antagonism, and modulation of endocannabinoid tone, among others. This pharmacological breadth underwrites its theoretical appeal but also complicates the pathway from bench to bedside.

The review finds that only two products have achieved full regulatory approval based on randomized controlled trial evidence: Epidiolex, a purified CBD formulation approved for refractory childhood epilepsy syndromes (Dravet and Lennox-Gastaut), and Sativex, a combined THC and CBD oromucosal spray approved for multiple sclerosis spasticity. The vast majority of commercially available cannabis-derived products, including oils, capsules, and whole-plant extracts, lack pharmaceutical-grade manufacturing controls (GMP, GLP, GAP) and are not supported by gold-standard clinical trial data for their marketed indications. Variable THC content and contamination with impurities in uncontrolled products represent particular risks for children, adolescents, and individuals predisposed to psychiatric disorders. The authors conclude that substantially more basic and clinical research, conducted under rigorous regulatory standards, is needed before broader cannabinoid indications can be responsibly expanded.

Dr. Caplan’s Take

This review does a valuable service by making explicit what many of us in cannabinoid medicine already know: the evidence base for CBD is real but remarkably narrow, and the commercial landscape has raced far ahead of it. When patients ask me about CBD for anxiety, sleep, or chronic pain, the honest answer is that the mechanistic story is compelling but the clinical trial evidence for most of those indications remains preliminary. The challenge is not that CBD is without promise but that most products patients encounter bear little resemblance to the pharmaceutical-grade formulations studied in the trials that do exist.

In practice, I counsel patients that if they choose to use CBD, product quality is the single most important variable they can control. I recommend products with certificates of analysis from accredited third-party laboratories and I emphasize that “CBD” on a label does not guarantee a standardized dose or absence of THC. For patients with refractory epilepsy, the evidence for Epidiolex is strong and actionable. For other conditions, I frame CBD as an area of active investigation rather than an established therapy, and I monitor closely for drug interactions, particularly with medications metabolized by CYP3A4 and CYP2C19.

Clinical Perspective

This review sits at a useful juncture in the research arc for CBD: enough evidence has accumulated to confirm CBD’s favorable safety profile and therapeutic value in specific epilepsy syndromes, but far too little exists to support the broad therapeutic claims attached to most commercial products. For clinicians, the key take-home is that the “entourage effect” hypothesis, frequently invoked to justify whole-plant or broad-spectrum extracts over purified CBD, remains too imprecise and insufficiently validated to guide clinical recommendations. The review does not invalidate interest in other cannabinoid indications but underscores that the evidentiary bar for responsible prescribing has not been cleared outside of epilepsy and MS spasticity.

From a pharmacological standpoint, CBD’s inhibition of CYP3A4 and CYP2C19 creates clinically meaningful drug interaction potential, particularly with antiepileptic drugs like clobazam, valproate, and common medications metabolized through these pathways. Hepatotoxicity signals have emerged in combination with valproate specifically. For vulnerable populations, including pediatric, adolescent, pregnant, and psychiatrically at-risk patients, uncontrolled THC exposure from non-pharmaceutical products represents a distinct and avoidable harm. The single most actionable recommendation clinicians can implement now is to counsel patients explicitly that product source and quality control matter as much as the molecule itself, and to document that conversation.

Study at a Glance

Study Type

Narrative review (non-systematic)

Population

Not applicable (review spans preclinical and clinical literature across multiple populations)

Intervention

CBD and cannabis-derived products (purified, combined, synthetic, whole-plant)

Comparator

Pharmaceutical-grade regulatory standards (GMP, GLP, GCP)

Primary Outcomes

Regulatory approval status, quality-control adequacy, and clinical evidence strength for CBD indications

Sample Size

Not applicable (narrative review; no PRISMA flow or article count reported)

Journal

Pharmaceuticals (MDPI, open access)

Year

2024

DOI or PMID

Not provided in source data

Funding Source

Not reported in source data

What Kind of Evidence Is This

This is a narrative review, which occupies a lower tier of the evidence hierarchy compared to systematic reviews and meta-analyses. Its literature search, while spanning five databases (PubMed, Embase, Web of Science, Scopus, Lilacs), was explicitly non-systematic, with no PRISMA flow diagram, no article count, and no formal risk-of-bias assessment. The single most important inference constraint this imposes is that the conclusions reflect the authors’ selective synthesis and interpretive framing rather than a reproducible, bias-controlled assessment of the totality of evidence.

How This Fits With the Broader Literature

The review’s conclusions align broadly with existing regulatory assessments and prior systematic reviews of cannabinoid therapeutics. The 2017 National Academies of Sciences report similarly found substantial evidence for cannabinoids in chronic pain, chemotherapy-induced nausea, and MS spasticity, while flagging insufficient evidence for most other marketed indications. More recently, systematic reviews of CBD for anxiety and chronic pain have reported promising signals but consistently highlighted small sample sizes, heterogeneous products, and short follow-up as limiting factors. This review extends the conversation by foregrounding the quality-control dimension, arguing that the gap between pharmaceutical-grade and commercially available products is itself a central barrier to generating reliable clinical evidence and protecting patients.

Common Misreadings

The most likely overinterpretation of this review is reading it as a definitive case that CBD “does not work” for conditions beyond epilepsy and MS spasticity. That exceeds what the evidence shows. The review’s actual argument is that the clinical trial evidence required for regulatory approval has not yet been generated for most other indications, not that such evidence will never materialize. Similarly, the authors’ skepticism toward the entourage effect should not be read as proof that multi-compound formulations are ineffective, but rather as a statement that the hypothesis remains insufficiently operationalized to drive drug development or prescribing decisions.

Bottom Line

This narrative review confirms that CBD has a favorable safety profile and proven efficacy in a narrow set of approved indications, while making clear that the commercial market has expanded far beyond the evidence base. It does not establish that CBD lacks potential for broader therapeutic use. For clinicians right now, the actionable message is straightforward: product quality and regulatory status matter enormously, and patients deserve transparent guidance about what the evidence does and does not support.

References

1. University of São Paulo, Ribeirão Preto Medical School. Narrative review on CBD pharmacology, efficacy, safety, and regulatory context. Pharmaceuticals (MDPI). 2024. DOI not provided in source data.
2. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. doi:10.17226/24625.